Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Cancer Stem Cells 2018

About Conference


Conference Series LLC Ltd cordially invites all the participants across the globe to attend the “Annual Congress on Cancer & Stem Cell Research” during October 17-18, 2018 at New York, USA which includes prompt Keynote presentations, Oral talks, Poster presentations and Exhibitions.

Cancer  Stem Cell 2018 is organized around the theme: “Cancer Stem Cell Research - Compassionate prevention, pursuit of excellence

Malignancy is a constitutive collection of maladies including anomalous cell development with the possibility of attack or spreading into different parts of the body. These diverge from generous tumors, which don't spread to different parts of the body. Possible signs and indications include protuberances, irregular dying, delayed hack, unexplained weight reduction, and an adjustment in solid discharges. While these side effects may demonstrate incidence of the disease, they may have different causes also. More than 100 sorts of diseases under this category influence people.

Malignancy is where a cell shows uncontrolled and abnormal division. Harmful cells can attack and decimates sound tissues and organs. An inquiry which is constantly raised whenever the disease is examined is the means by which it can be forestalled and identified prior to a critical stage. It is a special and whimsical perilous infection. There are for the most part 200 distinct sorts of cancer, each requiring particular and definitive methodologies for treatment. Disease Research is an immense field, understanding the causes, to whom and why it happens and how to dispose it off. Tumor dependably is an unpredictable inquiry, and there are no straightforward answers up until now. It is essential to examine and research malignancy as much could reasonably be expected. It can be fathomed just by the aggregate approach.

Target Audience:

Cancer Stem Cell Research Students, Scientists, Oncology Stem Cell  Researchers, Oncology Stem Cell Faculty, Medical Colleges, Scientists, Doctors, Professors, Oncology Lecturers, Researchers, Pharmaceutical IndustriesHealthcare Industries, Directors of cancer Stem Cell Associations and Societies, Cancer Stem Cell Training Institutes, Staff development educators, Cancer Stem Cell Specialists, Medical Devices Companies, Nurses .

Why to attend?

With people around the world focused on getting some answers concerning Cancer Stem Cell Research, keeping that as a prior concern in mind  this is your most obvious opportunity to accomplish the greatest social occasion of individuals from the Cancer Stem Cell Research gathering. This is your single most obvious opportunity to accomplish the greatest gathering of individuals from the Universities and mending focuses. Lead displays of new screening instruments, spread information about novel administrators and methods and meet with extremely reputed speakers in the fields of Cancer and stem cell.

Sessions/Tracks

1. Cancer Stem cells 

Cancer stem cells (CSCs) are cancer cells that contain distinguishing trait associated with normal stem cells, singularly the ability to give rise to all cell types found in a specific cancer sample. CSCs are therefore tumorigenic, possibly in contrast to other non-tumorigenic cancer cells. CSCs may create tumors through the stem cell processes of self-renewal and differentiation into multiple cell types. Such cells are hypothesized to continue in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors. Therefore, expansion of specific therapies targeted at CSCs holds hope for refinement of survival and quality of life of cancer patients, chiefly for patients with metastatic disease.

· Cancer stem cell markers

. Stem cell mutation

. Adult stem cells

. Metastasis

. Cancer stem cell therapy

2. Hematopoietic stem cells

Hematopoietic stem cells (HSCs) are the stem cells that give rise to blood cells through the operation of hematopoiesis. They are obtained from mesoderm and located in the red bone marrow, which is contained in the core of most bones. Hematopoiesis is the process by which all mature blood cells are produced. It must balance extensive production needs (>500 billion blood cells are produced every day) with the need to absolutely regulate the number of each blood cell type in the circulation. In vertebrates, the extensive majority of hematopoiesis occurs in the bone marrow and is obtained from a limited number of hematopoietic stem cells (HSCs) that are multipotent and capable of immeasurable self-renewal.

. Hematopoiesis

. Stem cell heterogeneity

. Multipotency and self-renewal

. Cluster differentiation and other markers

. Hematopoietic colonies and lineages

. HSC repopulation kinetics

3. Cancer stem cell model

The Cancer stem cell model, also known as the Hierarchical Model proposes that tumors are hierarchically organized (CSCs lying at the apex). Within the cancer population of the tumors, there are cancer stem cells (CSC) that are tumorigenic cells and are biologically separate from other subpopulations. They have two defining characters: their long-term capacity to self-renew and their ability to distinguish into progeny that is non-tumorigenic but still contributes to the growth of the tumor. This model proposes that only definite subpopulations of cancer stem cells have the capacity to drive the continuation of cancer, meaning that there are intrinsic characteristics that can be identified and then targeted to destroy a tumor long-term without the need to battle the whole tumor.

. Stochastic model

. Stem cell plasticity

. Somatic evolution

. Tumor-regenerative capacity

. Clonal evolution models

4. Regenerative medicine

Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs to initiate normal function". This field holds the commitment of engineering damaged tissues and organs by stimulating the body's own repair mechanisms to functionally heal previously unrepairable tissues or organs. Regenerative medicine also includes the probability of growing tissues and organs in the laboratory and embedding them when the body cannot heal itself. If a regenerated organ's cells would be derived from the patient's own tissue or cells, this would potentially resolve the problem of the shortage of organs available for donation, and the problem of organ transplant rejection.

. Tissue Engineering and Biomaterials

. Cellular therapies

. Medical devices and artificial organs

. Recapitulating Tissue and Organ Structure

. Integrating Graft Tissue by Inducing Vascularization and Innervation

. Cell Infusions and Modulating the Immune System

5. Stem cell niche

Stem-cell niche refers to a microenvironment, within the specific anatomic location where stem cells are found, which interacts with stem cells to regulate cell fate. The word 'niche' can be in reference to the in vivo or in vitro stem-cell microenvironment. Throughout the embryonic development, various niche factors act on embryonic stem cells to change gene expression, and influence their proliferation or differentiation for the development of the fetus. Within the human body, stem-cell niches maintain adult stem cells in a quiescent state, but after tissue injury, the surrounding micro-environment actively signals to stem cells to promote either self-renewal or differentiation to form new tissues. Several factors are important to regulate stem-cell characteristics within the niche: cell-cell interactions between stem cells, as well as interactions between stem cells and neighbouring differentiated cells, interactions between stem cells and adhesion molecules, extracellular matrix components, the oxygen tension, growth factors, cytokines, and the physicochemical nature of the environment including the pH, ionic strength (e.g. Ca2+ concentration) and metabolites, like ATP, are also important. The stem cells and niche may influence each other during development and reciprocally signal to maintain each other during adulthood.

. Germline stem cell

. Molecular mechanisms of GSC maintenance and activity

. Stem cell aging

. Epithelial-Mesenchymal transition

6. Different types of Cancer

Cancer is a group of diseases that include abnormal growth in the number of cells, with the capability to invade or spread to other parts of the body. Not all tumors or lumps are cancerous; benign tumors are not classified as being cancer because they do not spread to other parts of the body. There are over 100 different known cancers that affect humans. cancers are often described by the body part that they originated in. However, some body parts contain multiple types of tissue, so for greater precision, cancers are additionally classified by the type of cell that the tumor cells originated from.

. Carcinoma

. Sarcoma

. Lymphoma and leukemia

. Germ cell tumor

. Blastoma

. Primitive neuroectodernal tumor

. Oligodendroglioma

. Types of cancer based on size and shape

7. Chemotherapy

Chemotherapy (often abbreviated to chemo and CTX or CTx) is a category of cancer treatment that includes one or more anti-cancer drugs (chemotherapeutic agents) as part of a standardized chemotherapy regimen. Chemotherapy may be given with a curative intent (which almost always involves combinations of drugs), or it may aim to prolong life or to reduce symptoms (palliative chemotherapy). Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology.

. Treatment strategies

. Cytotoxics and targeted therapies

. Electrochemotherapy

. Hyperthermia therapy

. Chemotherapy regimens

. Adverse effects

. Cytostasis

8. Experimental Cancer stem cell treatments

Experimental cancer stem cell treatments are medical therapies intended or claimed to treat cancer by improving on, supplementing or replacing conventional methods (surgery, chemotherapy, radiation, and immunotherapy).

. Gene therapy

. Telomerase therapy

. Epigenic options

. Radiation therapy

. Electromagnetic treatments

. Nutrient microenvironment

9. Radiation-induced Cognitive decline

It describes the possible relation between radiation therapy and mild cognitive impairment. Radiation therapy is used mainly in the treatment of cancer. Radiation therapy can be used to cure care or shrink tumors that are obstructing with quality of life. Occasionally radiation therapy is used alone; other times it is used in combination with chemotherapy and surgery. For people with brain tumors, radiation can be a best treatment because chemotherapy is often less effective due to the blood–brain barrier. Woefully for some patients, as time passes, people who received radiation therapy may begin experiencing deficiency in their learning, memory, and spatial information processing capabilities. The learning, memory, and spatial information processing capabilities are dependent on proper hippocampus functionality. Consequently, any hippocampus dysfunction will result in deficits in learning, memory, and spatial information processing ability.

. Acute ablation of precursor cells

. Precursor cell integrity

. Alterations in hippocampus microenvironment

. Reversing the radiation induced cognitive decline

. Environmental enrichment

10. Cancer Stem Cells in Solid Tumours

Cancer stem cells (CSCs) are cells that cause tumorigenesis, as well as giving rise to a large population of differentiated progeny that make up the bulk of the tumor, but that have insufficient tumorigenic potential. CSCs have been identified in a variety of human tumors, as assayed by their capacity to initiate tumor growth in immunocompromised mice. Further characterization studies have revealed that gene expression profiles in breast cancer correlate with patient prognosis, and brain CSCs are specifically resistant to radiation through DNA damage repair. In extension, specific signaling pathways play a vital role in CSC self-renewal and/or differentiation, and previous studies indicate that CSCs are associated with a microenvironmental niche. Thus, the biological properties of CSCs are just beginning to be revealed, and the continuation of these studies should lead to the development of CSC-targeted therapies for cancer treatment.

11. Biomarkers of Cancer Stem Cells

Biomarker is a biological molecule found in blood, other body fluids, or tissues that is a signal of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.

To help diagnose conditions, as in the case of identifying early stage cancers (Diagnostic)

To forecast how aggressive a condition is, as in the case of determining a patient's ability to fare in the absence of treatment (Prognostic)

To predict how well a patient will respond to treatment (Predictive). 

. Imaging biomarkers

. Quantitative imaging biomarkers

12. Epigenetic Identity in Cancer Stem Cells

The Zuotin-related factor 1, ZRF1, has recently been identified as an epigenetic regulator of gene transcription in stem cells and cancer. During differentiation of human teratocarcinoma cells, ZRF1 promotes transcriptional induction of developmental genes that are repressed by Polycomb complexes.

13. Alternative Treatment and Cancer

Cancer can be treated by many methods, such as surgery, chemotherapy, hormonal therapy, radiation therapy, targeted therapy and synthetic lethality. People suffering from cancer can be investigated through medical tests. These generally include blood tests are X-rays, CT scans, and endoscopy. The tissue diagnosis from the biopsy indicates the type of cell that proliferates, through its histological grade, genetic abnormalities, and other features. Thus, all together it gives the user information about molecular changes such as mutations, fusion genes, and numerical chromosome to estimate or show the prognosis and to choose the best treatment. Cytogenetics and immunohistochemistry are other common tissue tests. The removal of cancer without damaging the other parts of the body (by achieving cure with near-zero adverse effects) is the main goal of treatment. The type of treatment depends on the type of cancer the patient is suffering from and how advanced it is. Some people with cancer have only one type of treatment. But for most of the people, they have a combination of treatments, such as surgery with chemotherapy (use of drugs to kill cancer cells) or radiation therapy. Immunotherapy, targeted therapy, or hormone therapy are another kind of treatment for cancer.

14. Cancer Immunotherapy & Nano Medicine

Cancer Immunotherapy is to treat the immune system which is having cancer. Immunotherapies can be divided as active, passive or hybrid (active and passive). These proceed towards to exploit the fact that cancer cells often have molecules on their surface that can be identified by the immune system, known as tumor-associated antigens(TAAs); they are usually proteins or other macromolecules (e.g. carbohydrates). It is found that active immunotherapy attacks the tumor cell by targetting TAAs under its direction. While passive immunotherapy enhances the existing anti-tumor response and will also include monoclonal antibodies.

. Targeted delivery method

. Cell tracking

. Tumor biology

. Nano systems

15. Nursing Oncology and Care

The field of oncology nursing, in particular, is probably one of the most challenging and rewarding fields in nursing. For those with cancer, oncology nurses are the ones who are there for us during our most difficult and intimate moments in life, the ones at our bedside, educating us, encouraging us. They are also the ones behind the scenes, communicating with our doctors, coordinating our care and keeping us safe. Thus, the advance nursing practice in oncology leads to mastery of the nursing process which provides the ability to guide, and evaluate nursing practice delivered to individuals diagnosed with cancer. The oncology nurse works expertly with the multidisciplinary oncology team to achieve realistic healthcare goals for an individual or for an entire community.

. Breast Care Nursing

. Surgical Oncology Nursing

. Chemotherapy Biotherapy

. Paediatric Haematology Oncology Nursing

. Assisting in cancer Care

. cancer Nursing Partnership

16. Cancer Bioinformatics and Clinical Medicine

Cancer bioinformatics deals with the organization and analysis of the data so that important trends and patterns can be identified – the ultimate goal being the discovery of new therapeutic and/or diagnostic protocols for cancer. In this, we will discuss some aspects of this revolution giving a special emphasis on Bioinformatics. Cancer bioinformatics is expected to play an important role in the identification and validation of biomarkers, specific to clinical phenotypes related to early diagnoses, measurements to monitor the progress of the disease and the response to therapy, and predictors for the improvement of patient’s life standard.

. DNA sequencing

. Microarray expression profiling

. Molecular interaction networks

. Single nucleotide polymorphisms

. Protein localization

17. Pediatric Oncology

The word pediatrics and its cognates mean "healer of children"; they derive from two Greek words: pais "child" and iatros "doctor, healer". The age limit, from birth up to 18-21 yrs. Pediatricians work both in primary care physicians and hospitals, especially the work in specialized subfields such as neonatology. Paediatric oncologists diagnose, treat, and manage children, suffering from cancers which include leukaemia, lymphomas, brain tumours, bone tumours, and solid tumours. A medical practitioner who specializes in this area is called as a paediatrician or paediatrician. The body of an infant or neonate is substantially physiologically different when compared to an adult. Congenital defects, genetic variance, and developmental issues are some greater concern to paediatricians as compare to adult physicians.

. Neuroblastoma

. Wilms a tumour

. Retinoblastoma Osteosarcoma

. Ewing sarcoma

. Pleuropulmonary blastoma (lung or pleural cavity)

. Pediatric cancer: Case Report

. Novel Therapies in Pediatric oncology

18. Cancer Awareness and Survival

Cancer awareness is an attempt to raise awareness and reduce the stigma of cancer through education on symptoms and treatment. Supporters hope that better knowledge will lead to earlier discovery of breast cancer, which is associated with higher long-term survival rates, and that money raised for cancer will produce a reliable, permanent cure. Cancer survival rates vary by the type of cancer, stage at diagnosis, treatment given and many other factors, including country. In general survival rates are improving, although more so for some cancers than others. Survival rate can be measured in several ways, median life expectancy having advantages over others in terms of meaning for people involved, rather than as an epidemiological measure.

19. Cancer Pain Management

Cancer pain treatment purposes to release pain with slight adverse effects, allowing the person a good quality of life and level of function and a relatively painless death. Though 80-90 percent of cancer pain can be controlled, half of the people with cancer pain in the developed world and more than 80% of people through cancer worldwide receive less than best care. Cancer changes over time, and pain managing needs to reflect this. Some different types of treatment may be required as the disease progresses. Pain managers should clearly explain to the person the cause of the pain and the various treatment possibilities, and should consider, as well as drug therapy, directly modifying the underlying disease, raising the pain threshold, interrupting, destroying or stimulating pain pathways, and suggesting lifestyle modification.

20. Cancer Prognosis

Different factors affect a person's prognosis. Some of the most important are the type and location of the cancer, the extent to which the cancer has metastasized, or spread and how uncommon the cancer cells look and how quickly the cancer is likely to grow and spread. In addition, for cancers of the blood or bone marrow such as leukemias and lymphomas, the presence of chromosomal abnormalities and abnormalities in the patient's complete blood count can affect a person's prognosis. Researchers usually give survival statistics as rates. The rates describe the percentage of people with a specific cancer type who will be alive a certain time after diagnosis. Survival rates can describe any given length of time.

21. Carcinogenesis and Mutagenesis

Carcinogenesis is the emergence of a cancer, whereby normal cells are deformed into cancer cells. The process is takes place by changes at the cellular, genetic, and epigenetic levels and abnormal cell division, in some cancers developing a malignant mass. Cell division is a physiological procedure that occurs in almost all tissues and under different circumstances. A mutagen is a physical or chemical agent that changes the genetic material, usually DNA, of an organism and thus increases the frequency of mutations above the natural background level. As many mutations can cause cancer, mutagens are therefore also likely to be carcinogens, while not always necessarily.

22. Cancer Genomics and Metabolomics

Cancer genomics is the study of the totality of DNA sequence and gene expression differences between tumour cells and normal host cells. It targets to understand the genetic basis of tumour cell proliferation and the evolution of the cancer genome under mutation and selection by the body environment, the immune system and therapeutic interventions. Metabolomics research is being used to discover diagnostic cancer biomarkers in the clinic, to better understand its complex heterogeneous nature, to discover pathways involved in cancer that could be used for new targets and to monitor metabolic biomarkers during therapeutic intervention. These metabolomics approaches may also provide clues to personalized cancer treatments by providing useful information to the clinician about the cancer patient’s response to medical interventions. The ultimate goal of most metabolomics cancer studies is to discover cancer-specific diagnostic, prognostic or predictive biomarkers for a patient.

23. Genetically modified Stem Cell Therapy

An experimental method which uses the genetic cell in the modification of the stem cells in the treatment or prevention of the disease is referred to as the combined Gene and Stem cell therapy. This in general effect the course of different genetic and multi factorial diseases at the DNA/RNA level. The stem cells used in the gene therapy is a viable one which has a more consequence for treating a variety of diseases, where most don’t have a cure.

. Somatic Cell Therapy

. Stem cell secretome

. Immunological Changes in the stem cell

. Cord Blood Stem Cell

. Disease modeling and drug development

. Organ synthesis

. Tissue repair

. Clinical trial

24. Cancer Stem Cell-targeted Therapy and the development of drug carriers

There are three main strategies for conventional Cancer therapy: surgical resection, chemotherapy, and radiotherapy. Surgical resection is still the most potent means to treat certain tumors. However, it has notable limitations: resection cannot cure metastatic cancer completely, and it does not work in hematopoietic cancer therapy. Resection may also influence physical function since excision may remove some normal tissues, causing sequelae. CSCs are known to be resistant to chemotherapy and radiotherapy. Failure to completely eliminate CSCs with these approaches leads to disease recurrence. Cancer stem cell theory has created a new prospect for cancer therapy targeting CSCs. Therefore, CSC-targeted therapy should be an important part of cancer therapy.

25. Development of Cancer Stem cell-targeted nano-drug carriers

Most anti-cancer agents cannot target cancer cells actively. Furthermore, commonly used anti-cancer agents are toxic to all kinds of cells, causing side effects in normal tissues when homogeneously distributed in the circulation system. Thus, choosing a proper carrier for anti-cancer agent loading and transport to the lesion site can decrease the toxic side effects and produce better therapeutic effects. The development of nanotechnology has created novel opportunities for drug carrier research. Nanomaterials consist of nanoscale elementary units, which possess special properties. Nanomaterial, especially the composites assembled by nanoscale units, have many advantages in loading drugs, including high drug load content, favorable drug metabolism control when the surface of the material is modified, good distribution and controlled release. Furthermore, some are biodegradable and biocompatible, and some can target specific organs, organelles, or tissues. Nanomaterials commonly applied in drug delivery include nanoparticles, e.g., inorganic nanoparticles, polymeric nanoparticles, or liposomes; nanotubes, e.g., carbon nanotubes and quantum dots. Each has particular characteristics and drug-loading capabilities. Combining nanomaterials with antibodies against CSC-specific markers or CSC-targeting agents may be a useful strategy in CSC-targeting therapy.

. Liposomes

. Micelles

. Polymeric nanoparticles

. Gold nanoparticles

26. Cancer Stem cells detection and diagnosis

Many tumors produce substances that are used as tumor markers in cancer diagnosis. However, the assessment of these markers alone does not lead to the conclusion that the patient has the disease. The use of biomarkers for CSC would be an additional alternative for detection. Furthermore, high levels of these tumor markers appear when the tumor is already installed, while the use of cancer stem cells would allow detecting the tumor at a very early stage. The knowledge of cancer stem cells and their markers can help differentiate tumors by type, taking into account their location. It is also possible to evaluate the degree of tumor aggressiveness according to the phenotype of these cells. Taking the example of breast cancer, CD44-CD24cells are more invasive and have greater proliferative potential than that of CD44-CD24 cells. Furthermore, the screening of CSCs could be used in the diagnosis of possible metastasis since these cells are highly tumorigenic and have migratory capacity.

 

Applications of Stem Cell in Cancer

Stem cells have been for quite some time set up in tumor treatment. Stem cells have been connected in the treatment of genuine maladies for over 55 years. They are connected particularly to treat growths, which require high-measurements chemotherapy inside the extent of restorative care.

Types of Stem Cell Transplants for Cancer Treatment

In a typical stem cell transplant for cancer very high doses of chemo are used, sometimes along with radiation therapy, to try to kill all the cancer cells. This treatment also kills the stem cells in the bone marrow. Soon after treatment, stem cells are given to replace those that were destroyed. These stem cells are given into a vein, much like a blood transfusion. Over time they settle in the bone marrow and begin to grow and make healthy blood cells. This process is called Engraftment.

There are 2 main types of transplants. They are named based on who gives the stem cells.

Autologous stem cell transplants

In this type of transplant, your own stem cells are removed, or harvested, from your blood before you get treatment that destroys them. Your stem cells are removed from either your bone marrow or your blood, and then frozen. After you get high doses of chemo and/or radiation, the stem cells are thawed and given back to you.

Allogeneic stem cell transplants

Allogeneic stem cell transplants use cells from a donor. In the most common type of allogeneic transplant, the stem cells come from a donor whose tissue type closely matches the patient’s The best donor is a close family member, usually a brother or sister. If you don’t have a good match in your family, a donor might be found in the general public through a national registry. This is sometimes called a MUD (matched unrelated donortransplant. Transplants with a MUD are usually riskier than those with a relative who is a good match.

Stem Cell Transplants in Cancer Treatment

Stem cell transplants are procedures that restore blood-forming stem cells in people who have had theirs destroyed by the very high doses of chemotherapy or radiation therapy that are used to treat certain cancers.

Blood-forming stem cells are important because they grow into different types of blood cells. The main types of blood cells are:

·        White blood cells, which are part of your immune system and help your body fight infection.

·        Red blood cells, which carry oxygen throughout your body.

·        Platelets, which help the blood clot.

How Stem Cell Transplants Work against Cancer

Stem cell transplants do not usually work against cancer directly. Instead, they help you recover your ability to produce stem cells after treatment with very high doses of radiation therapy, chemotherapy, or both.

However, in multiple myeloma and some types of leukemia, the stem cell transplant may work against cancer directly. This happens because of an effect called Graft-versus-tumor that can occur after allogeneic transplants. Graft-versus-tumor occurs when white blood cells from your donor (the graft) attack any cancer cells that remain in your body (the tumor) after high-dose treatments. This effect improves the success of the treatments.

Current Stem Cell Treatments for Cancer

Adult stem cells have been used for decades to treat certain cancers through bone marrow transplants. In this therapy, the stem cells that give rise to the different blood cells in the body are transplanted into the bone marrow of the patient, where they regenerate the blood. This is a vital and often life saving treatment because chemotherapy destroys the bone marrow alongside cancer cells and the blood cells must be replenished for the patient's treatment to be successful. It is hoped that the molecular basis for this treatment can lead to similar treatments for other forms of cancer, allowing for cancerous tissues in areas such as the brain to receive stem cells that replenish those that are damaged through radiation.

Stem Cell Development and Cancer

When cancers develop in different tissues, they can still have similar genetic abnormalities. An important scientific focus is to identify all of these genetic abnormalities and develop treatments to combat the effects. To properly identify all of these abnormalities, however, scientists need to learn more about stem cell characteristics at the various developmental stages. By examining the developmental process of healthy stem cells, scientists can better gauge how abnormal differentiation occurs and may then be able to develop treatments to prevent or treat the abnormalities. An understanding of how stem cell differentiation and specialization are controlled is another fundamental development process that researchers need to grasp in hopes of creating effective cancer treatments.

Because cancer rates have significantly increased over the last century and the incidence is such that even if you do not suffer from cancer in your lifetime, you will likely know someone who does, stem cell research must continue in this area. The chance to save lives and decrease suffering is exactly the sort of motivation that should support further stem cell studies for cancer treatments.

 

 

Market Analysis

MARKET ANALYSIS

About the Annual Congress on Cancer and Stem Cell Research 2018

Cancer Stem Cells 2018 provides a unique platform to explore and learn about the recent developments in the field of cancer, stem cell, biological and translational areas of Oncology and Stem Cell Biology. A thought provoking rendezvous by esteemed and renowned scholars around the world will put forth their expertise and experience in tackling the cancer and taking the cancer research to the heights.

History of Cancer Stem Cell Research

The stem cell principle of cancer proposes major standards:

 i) That cancers arise from stem cells that are present within the tissues of each children and adult individuals; and

 ii) That cancers are composed of the same types of cells as are normal tissues, ie, stem cells, transit amplifying cells, and terminally differentiated cells.

The hypothesis that cancers arise due to maturation arrest of stem cells was proposed in 1994 for all tissues based primarily on observations of the origin of teratocarcinomas and hepatocellular carcinomas. About the same time, tumor transplantation studies led to renewed interest in the concept that cancers were maintained by a small fraction of the cells in the cancer that have the properties of stem cells. In this review, the involvement of stem cells, as the cells of origin of cancer, in each of the major theories of the origin of cancer using selected example of cancers will be documented, and from this models that describe the nature of the cells in a cancer will be provided.

Cancer Stem Cells Market Value:

·The worldwide market for cancer stem cells will grow from $745 million in 2017 to $1.9 billion by 2022 with a compound annual growth rate (CAGR) of 21.2% during 2017-2022.

·Leukemia stem cells market will grow from $240 million in 2017 to $606 million by way of 2022 with a CAGR of 20.4% during 2017-2022.

·Breast cancer stem cell market will grow from $171 million in 2017 to $449 million by of 2022 with a CAGR of 21.3% during 2017-2022.

Desires and Goals of Market Reports :
• Identify  key market segments and market structure in cancer stem cells technologies
• Measure in addition to estimate the worldwide cancer stem cells market and its market segments, which consist of cancer type and geographic segmentation. 
• Identify key market dynamics and the factors impacting the worldwide cancer stem cells marketplace and its subsegments. 
• Recognizes the tendencies, gaps, and possibilities in each of the micromarkets
• Attention on geographic segmentation. Examine traits and possibilities in main regions: North America, Europe, Asia-pacific, and the rest of the world (ROW).

• Identify major stakeholders, product portfolio and current tendencies and draw a competitive landscape for the marketplace leaders.

The most prominent candidates for cancer stem cells market :

Company

   Lead product

Compound type

FDA approved

Indication

 

Glaxo Smith kline

 

Tyverb

(Lapatinib)

 

Small molecule

 

FDA approved

 

Breast cancer

 

ChemGenex(Melbourne,Australis/Menlo Park California)

 

Omacetaxine

Mepesuccinate

 

ND

 

Phase2/3

 

Chronic myeloid leukemia

 

Geron (Menlo Park,California)

 

GRN 163L

 

Small molecule

 

Phase1/2

 

Solid tumors

 

Stemline Therapeutics(New York)

 

SL-401

 

Recombinant protein toxin

 

Phase 1

 

AML and myelodys-plastic syndrome

 

Onco Med Pharmaceuticals/Glaxo SmithKline

 

OMP-21M18

 

mAB

 

Preclinical

 

Prostate and colon cancer

 

Raven/Vaxgen

 

RAV17/RAV18

 

mAB

 

Preclinical

 

colon and prostate  cancers

 

Arius Research(Toronto)

 

ARH460-16-2

 

MAB

 

Preclinical

 

Leukemia,breast,colon and prostate  cancers

 

Immunocellular Therapeutics(LosAngeles)

 

ICT-111

 

Dendritic cell-based vaccine

 

Preclinical

 

Glioblastoma

               

Cancer stem cells market is divided into four main segments such as Europe, North America, Asia Pacific and Rest of the World (RoW). With virtue of technological advancements and enhanced healthcare infrastructure North America holds the upper hand in worldwide cancer stem cells market. Asia Pacific region is expected to grow at a profitable rate during the forecast period due to the rapidly improving healthcare facilities, increase in prevalence of cancer, increasing healthcare expenditure levels, upsurge in research and development activities related to cancer and increasing patient awareness in the emerging market of the globe.

To Collaborate Scientific Professionals around the World

Conference Date October 17-18, 2018

For Sponsors & Exhibitors

sponsors@conferenceseries.com

Speaker Opportunity

Supported By

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by